Eli Lilly may have downplayed the risk of its top-selling schizophrenia drug - Zyprexa. Mike Huckman, CNBC Pharmaceuticals Reporter, and Erin Burnett discuss the details.
Topics:
Pharmaceuticals | Stock Market
COMMENTS
Thank you for joining our discussion. Your comment has been posted.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT